RELAY THERAPEUTICS INC (RLAY) Stock News
NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD
RLAY Latest News, Press Relases and Analysis
BofA Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. On May 14, Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Sana Biotechnology, Inc. (NASDAQ:SANA) and set a price target of $6.00. The rating update came after the company announced on May 12 […]
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
Mentions: BCAX
Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial
Avidity Biosciences, Inc. (NASDAQ:RNA) revealed topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE program in Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a genetically acquired disease that leads to progressive muscle weakness and severely decreased functional capacity. The data will be presented at the 32nd Annual FSHD Society International Research Congress. Also Read: Avidity Biosciences Touts Positive Data From Early-Stage D
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc. (RLAY)’s share was trading at $3.23 as of 4th June. Relay Therapeutics is gaining momentum in oncology, thanks to promising data from its PI3Kα inhibitor RLY-2608, unveiled at […]
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2-...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...
Snowflake Inc. (NYSE:SNOW): Offering Sustained Growth and Lucrative Returns
We came across a bullish thesis on Snowflake Inc. (NYSE:SNOW) on ValueInvestorsClub by Wells. In this article, we will summarize the bulls’ thesis on SNOW. The company’s shares were trading at $147.56 when this thesis was published, vs. the closing price of $158.96 on Apr 28. SNOW provides a cloud-based data platform for various organizations […]
Core & Main, Inc. (NYSE:CNM): Better Days in the Pipeline
We came across a bullish thesis on Core & Main, Inc. (NYSE:CNM) on ValueInvestorsClub by yellow. In this article, we will summarize the bulls’ thesis on CNM. The company’s shares were trading at $48.00 when this thesis was published, vs. the closing price of $52.53 on Apr 25. CNM distributes water, wastewater, storm drainage, and […]
Bank of England set to cut rates amid worries about Trump tariff fallout
LONDON (Reuters) -The Bank of England is poised to extend its slow run of interest rate cuts on Thursday with investors watching for any signs that it could soon pick up the pace as U.S. President Donald Trump's tariffs weigh on the world economy. Governor Andrew Bailey and his BoE colleagues have long stressed the need for a gradual and careful approach to lowering borrowing costs, something most analysts say is likely to continue given the scale of uncertainty about the outlook. The BoE has cut rates just three times so far since last August, moving more slowly than the U.S. Federal Reserve and the European Central Bank due to its concerns about inflationary heat in the jobs market.
Qualys, Inc. (QLYS): A Bull Case Theory
We came across a bullish thesis on Qualys, Inc. (QLYS) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on QLYS. Qualys, Inc. (QLYS)’s share was trading at $126.82 as of May 5th. QLYS’s trailing and forward P/E were 27.27 and 21.74 respectively according to Yahoo Finance. Qualys, Inc. (QLYS) is a […]
DexCom, Inc. (DXCM): A Bull Case Theory
We came across a bullish thesis on DexCom, Inc. (DXCM) on Substack by Na’s Substack. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc. (DXCM)’s share was trading at $81.53 as of May 5th. DXCM’s trailing and forward P/E were 61.30 and 40.65 respectively according to Yahoo Finance. Dexcom, Inc. stands at the […]
Marex Group plc (MRX): A Bull Case Theory
We came across a bullish thesis on Marex Group plc (MRX) on Substack by Karst Research. In this article, we will summarize the bulls’ thesis on MRX. Marex Group plc (MRX)’s share was trading at $45.65 as of May 5th. MRX’s trailing and forward P/E were 16.78 and 13.37 respectively according to Yahoo Finance. Marex has quietly […]
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical...
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming...
Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts
We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other promising penny stocks. Solus’ Dan Greenhaus, and Invesco’s Brian Levitt together appeared on CNBC’s ‘Closing Bell’ on April 15 to talk […]
Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?
We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of […]
Is PayPal Holdings Inc. (NASDAQ:PYPL) the Most Undervalued Quality Stock to Buy Now?
We recently published a list of the 11 Most Undervalued Quality Stocks to Buy Now. In this article, we are going to take a look at where PayPal Holdings Inc. (NASDAQ:PYPL) stands against other undervalued quality stocks to buy now. On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined ‘The Exchange’ on […]
Intel Growth Challenges Are Not Over Despite Altera Stake Sale: Analyst
JP Morgan analyst Harlan Sur reiterated an Underweight rating on Intel Corp (NASDAQ:INTC) on Tuesday, setting a price forecast of $23. On Monday, before the market opened, Intel announced a 51% stake sale of its programmable chip business, Altera, to private equity firm Silver Lake Management for $4.46 billion, valuing Altera at $8.75 billion with a transaction multiple of ~5.7 times calendar 2024 sales. As a reference, Intel bought Altera in 2015 at 9 times calendar 2014 sales and in 2020, and
Domo, Inc. (DOMO): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout
We recently published a list of 20 Stocks Insiders Bought in April After Trump’s Tariff Rollout. In this article, we are going to take a look at where Domo, Inc. (NASDAQ:DOMO) stands against other stocks that insiders bought in April after Trump’s tariff rollout. President Donald Trump called April 2 a “Liberation Day” after signing […]
Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Relay Therapeutics, Inc. (NASDAQ:RLAY) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines!
We recently published a list of Top 9 AI Ratings and News Updates on Wall Street’s Radar. In this article, we are going to take a look at where Relay Therapeutics Inc. (NASDAQ:RLAY) stands against other top AI ratings and news updates on Wall Street’s radar. Despite AI’s potential to transform our lives for the […]
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2-...
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the...